Loading news...
Pluri Inc. (NASDAQ: PLUR - Get Free Report) was the target of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 22,147 shares, an increase of 22.7% from the January 15th total of 18,051 shares. Approximately 0.3% of the company's shares are sold short. Based
HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. (“Remedy Cell”), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.
Pluri Inc. (NASDAQ: PLUR - Get Free Report) shares dropped 12.7% during trading on Thursday. The stock traded as low as $3.04 and last traded at $3.09. Approximately 121,244 shares traded hands during trading, an increase of 136% from the average daily volume of 51,287 shares. The stock had previously closed at $3.54. Analyst Ratings
Plurilock Security Inc. ( PLUR:CA ) Q3 2025 Earnings Call November 27, 2025 11:00 AM EST Company Participants Ian Paterson - CEO & Director Scott Meyers - CFO & Corporate Secretary Conference Call Participants Ryan Freemantle Presentation Ryan Freemantle Good morning, and thank you for joining us for Plurilock Securities conference call to discuss its financial results for the quarter ending September 30, 2025. I'm Ryan Freemantle from Sophic Capital, and we handle Plurilock's Investor Relations.